Further upside potential for ResMed: RBS Morgans
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
ResMed (RMD) shares have more room for gains despite their recent run-up over the past month as the company's earnings strengthen and the Australian dollar provides greater tailwinds, according to RBS Morgans.
The broker upgraded the medical device maker's stock to "outperform" from "neutral", seeing a nearly 10% upside with a target price of $5.97.
While RBS Morgans realises ResMed's prices will further soften in the face of competitive pressures in the US, it thinks the company will be able to deal with this in a variety of ways – given management's ability to maintain margin stability so far – including cost-outs, manufacturing efficiencies and more volume-based deals.
The broker forecasts the benefits from the weakening Australian dollar to contribute 0.7% to the company's gross margin in the first quarter of 2013-14, with greater benefits in the second quarter.
ResMed's forward price-earnings (P/E) ratio at 19 times isn't too demanding "given [the company's] ability to deliver double-digit earnings growth, further increase capital management and gain from an environment where other sectors remain out of favour," according to the broker.
Call 1300 880 160
Start a chat
Schedule a call
